Kyle Seamon

Company: Revolution Medicines Inc.

Job title: Senior Scientist II

Seminars:

Targeting Oncogenic RAS(ON) by Engaging Cyclophilin A & Inducing Inhibitory Tri-Complexes 4:15 pm

Design of natural product-inspired molecules that induce a tri-complex between Cyclophilin A and the active state of RAS Tri-complex inhibitors of RAS(ON) are potent, orally bioavailable, and active in vivo in preclinical models of RAS-driven cancers Formation of tri-complex enables novel bRo5 functionality, including covalent targeting of mutations beyond KRASG12CRead more

day: Conference Day One